Randomised, Double Blind, Placebo Controlled Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy.

Trial Profile

Randomised, Double Blind, Placebo Controlled Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Lu AA 24493 (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; Biomarker
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 08 Jun 2011 Planned end date changed from 1 May 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top